Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2018 Earnings Conference Call Transcript
Feb 07, 2019 • 04:30 pm ET
Good day, ladies and gentlemen, and welcome to the Pulse Biosciences Investor Update Conference Call. At this time, all participants are in a listen-only. Later, we will conduct a question-and-answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this conference call is being recorded.
I will now like to turn the conference over to Brian Dow, Pulse Biosciences' Senior Vice President and Chief Financial Officer. Sir, you may begin.
Thank you. And good afternoon, everyone. Welcome to Pulse Biosciences fourth quarter 2018 investor and analyst update call.
On the call with me today are Darrin Uecker, our President and Chief Executive Officer; and Ed Ebbers, our Executive Vice President and General Manager of Dermatology.
Before we begin, I would like to remind you that on today's call, we will be making forward-looking statements. These include statements regarding our plans, intentions and expectations relating to our commercial, operational, scientific, clinical and financial projections, financing plans, products, including the uses and applications of such products and other future events. You should not place undue reliance on such forward-looking statements as they are subject to a number of assumptions, risks and uncertainties, and may differ materially from actual results. These risks and uncertainties are more fully described in our Securities and Exchange Commission filings, including our Annual Report on Form 10-K and mostly recently filed Quarterly Report on Form 10-Q. Investors are encouraged to reference these risks, uncertainties and other disclosures in those reports. Pulse Biosciences undertakes no obligation to update forward-looking statements as a result of new information or future events.
In addition, today's call is being recorded and will be available for audio replay on the Investors section of our website at www.pulsebiosciences.com shortly after the conclusion of the live call. Investors electing to use the audio replay are cautioned that forward-looking statements made on today's call may differ or change materially after the completion of the live call.
I would now like to turn the call over to our President and Chief Executive Officer, Darrin Uecker.
Darrin R. Uecker
Thanks, Brian. Good afternoon, everyone and thank you for taking time to join us on today's call.
2018 was a very productive and important year in our mission to become a viable company at Pulse Biosciences. Before reviewing our progress in 2018 and how this is driving our milestones in 2019, the most important thing we want our shareholders and partners to understand today is that we have a clear vision for the commercialization of our CellFX System in aesthetic dermatology in 2019 and we believe this provides us a clear path to viability. Our mission -- our vision for our CellFX system in aesthetic dermatology is clear. Our CellFX system is a platform and we will deliver a growing array of valuable applications through the CellFX platform that patients will desire and aesthetic dermatology clinics will be excited to deliver for their patients. Our initial commercial applications will be in seborrheic keratosis, a common raised benign pigmented lesion on